EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)—multicenter real-world analysis from Germany and comparative review of the literature
Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers
The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Clinicians and patients perspectives on follow-up care and eHealth support after allogeneic hematopoietic stem cell transplantation: A mixed-methods contextual analysis as part of the SMILe study
Theory-driven development of a medication adherence intervention delivered by eHealth and transplant team in allogeneic stem cell transplantation: the SMILe implementation science project
Covid‐19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy
Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
Strength and muscle mass loss with aging process. Age and strength loss
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis
Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia
Allogeneic Transplantation in Multiple Myeloma: Long-Term Follow-Up and Cytogenetic Subgroup Analysis
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network